Topas Therapeutics brings in new CMO

pharmafile | November 1, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Topas Therapeutics, biotech, drugs, pharma, pharmaceutical 

Topas Therapeutics, a German company focused on developing novel therapeutics to treat immune-mediated and autoimmune diseases, announced that it has brought in Rupert Sandbrink into the newly created position of Chief Development Officer and Chief Medical Officer.

Sandbrink began his career in the pharmaceutical industry as clinician for Schering AG, where he worked for close to a decade before its eventual acquisition by Bayer; the last position he held before the merger was as Vice President and Head of Global Medical Developments Specialized Therapeutics.

Upon joining Bayer, Sandbring held the role of Vice President and Head of Global Clinical Development Neurology, Ophthalmology, Hematology and Immunology. He stayed at Bayer for other 9 years before moving onto the Danish pharma company, Forward Pharma. He performed the role of Executive Vice President of Multiple Sclerosis/Neurology & Immunology.

Sandbrink left his position at Forward Pharma after a year and a half to take up his new position at Topas. During the last decade, he has held a position as Lecturer at the University of Dusseldorf and is the author of more than 80 scientific and review articles.

Sandbrink commented on his appointment: “I am excited to have the opportunity to join Topas as the company prepares its first programs for clinical development. I am impressed with the company’s novel technology platform and also with the board and its strategy to support the company. I look forward to driving Topas’ development efforts and advancing our exciting programs into and through the clinic and the regulatory process.”

Timm Jessen, Chief Executive Officer of Topas Therapeutics, said: “Rupert has a long and successful track record of bringing drugs and biologics through clinical development and regulatory approval. While at Bayer/Schering, he led global clinical development for a variety of programs and is well versed in trial development and in interacting with regulatory agencies. He also has experience in a variety of innovative therapeutic technologies, including gene therapy, cell therapy and nanotechnology. He brings the critical expertise and experience that will help us immensely as we advance and prepare to enter our first program into the clinic. I am very excited to have him join the Topas team.”

For Topas, it represents another signal of growth for the company – coming not long after it announced that it had signed a deal with Eli Lilly to develop compounds targeting inflammatory and autoimmune diseases.

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content